Clinical Trial: NCT07088913
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-03-03 |
Study Overview
Brief Summary
The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.
Official Title
An Open-label, Fixed-sequence Study to Assess the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin (a BCRP, OATP1B1 and OATP1B3 Sensitive Substrate) in Healthy Participants
Conditions
Healthy Participants
Intervention / Treatment
- Drug: Capivasertib
- Drug: Rosuvastatin
Other Study ID Numbers
- D3615C00006
Start Date (Actual)
2025-07-28
Primary Completion Date (Actual)
2026-02-20
Study Completion Date (Actual)
2026-02-20
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-03-03 |
Study Overview
Brief Summary
The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.
Official Title
An Open-label, Fixed-sequence Study to Assess the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin (a BCRP, OATP1B1 and OATP1B3 Sensitive Substrate) in Healthy Participants
Conditions
Healthy Participants
Intervention / Treatment
- Drug: Capivasertib
- Drug: Rosuvastatin
Other Study ID Numbers
- D3615C00006
Start Date (Actual)
2025-07-28
Primary Completion Date (Actual)
2026-02-20
Study Completion Date (Actual)
2026-02-20
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 1